Jump to navigation Jump to search

Template:Chembox new

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Aleglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by Hoffmann–La Roche for the treatment of type II diabetes. It is currently in phase II clinical trials.[1]


  1. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. Retrieved 2008-03-19.

Template:Pharma-stub Template:Oral hypoglycemics

Template:WH Template:WS